{
    "Trade/Device Name(s)": [
        "Afinion HbA1c Dx",
        "Afinion\u2122M HbA1c Dx"
    ],
    "Submitter Information": "Alere Technologies AS",
    "510(k) Number": "K180296",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121610"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "May 7, 2018",
    "Summary Letter Received Date": "February 6, 2018",
    "Submission Date": "April 26, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c (HbA1c)",
        "Total hemoglobin"
    ],
    "Specimen Type(s)": [
        "Venous whole blood",
        "Capillary whole blood",
        "Fingerstick whole blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "Integrated sampling device"
    ],
    "Instrument(s)/Platform(s)": [
        "Alere Afinion AS100 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Boronate affinity assay",
        "Reflectance measurement"
    ],
    "Methodologies": [
        "Quantitative boronate affinity testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Test",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Afinion HbA1c Dx quantitative boronate affinity assay for HbA1c on the Alere Afinion AS100 Analyzer to aid diabetes diagnosis and risk assessment",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative determination of glycated hemoglobin (HbA1c) in human venous and capillary whole blood, used as an aid in diagnosis of diabetes and in identifying patients at risk for developing diabetes",
    "fda_folder": "Clinical Chemistry"
}